- International Diploma in Medicinal Cannabis for Latin American
doctors to be hosted virtually through Mexico's TecSalud School of Medicine and
Health Sciences (EMCS), beginning February
20, 2021
- Physicians from Mexico and
across Latin America will
participate in a fee-based 6-week diploma program
- Diploma marks a historic advance in medical education around
the prescription of medicinal cannabis in Mexico and the Latin
America region
- Mexico emerges as a key player
in the global medical cannabis market following the signing of
legislation in January 2021
- Khiron plans to build on the success of its vertically
integrated model in Colombia,
expanding the Company's Zerenia medical cannabis clinics across
major cities in Mexico
TORONTO, Feb. 23, 2021 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF)
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, today announces the Company has
introduced Latin America's first
internationally accredited post graduate medical cannabis program.
Hosted in partnership with Mexico's TecSalud School of Medicine and
Health Sciences, this first of its kind program provides essential
medical cannabis education to practicing doctors and comes as
Khiron plans to roll out its satellite clinic and market awareness
strategy in Mexico.
"Our goal is to improve the lives of 1 million patients by 2024,
and Mexico is a very important
part of that plan. The success of our partnership with Tecnologico
de Monterrey allows us to now
introduce the first internationally recognized medical cannabis
diploma program in Latin America.
We are very enthusiastic about our role in the legal medical
cannabis market in Mexico and
believe that an educated physician community, together with our
proven, vertically integrated model, will give us a significant
first mover and sustainable advantage in the country," comments
Alvaro Torres, Khiron CEO and
director.
The medical diploma will be delivered virtually through the
TecSalud School of Medicine and Health Sciences, starting in
February 2021, to provide physicians
with the necessary tools for the responsible use and safe
prescription of cannabinoids. The program will cover the
theoretical and practical basis of medical cannabis,
pharmacological properties of cannabinoids, and the international
regulatory frameworks for medical cannabis. The diploma course will
be delivered through keynotes, expert panels and workshops with
international speakers and pioneers in the field of medicinal
cannabis. Dr. Fernando Cantú, the Academic Director of the Medical
Specialty of Anesthesiology and Clinical Director of the Clinic of
Pain and Palliative Care at TecSalud will oversee the program.
About Khiron Life Sciences Corp.
Khiron is a
vertically integrated medical and CPG cannabis company with core
operations in Latin America, and
operational activity in Europe and
North America. Khiron is the
leading medical cannabis provider in Colombia and the first company licensed in
Colombia for the cultivation,
production, domestic distribution and sales, and international
export of both low and high THC medical cannabis products. The
Company has filled medical cannabis prescriptions in Colombia, Peru and the UK, and is positioned to commence
sales of medical cannabis in Germany and Brazil in early 2021.
Leveraging wholly-owned medical clinics and proprietary
telemedicine platforms, Khiron combines a patient-oriented
approach, physician education programs, scientific expertise,
product innovation, and agricultural infrastructure to drive
prescriptions and brand loyalty. Its Wellbeing unit launched the
first branded CBD skincare brand in Colombia, with Kuida™ now marketed in multiple
jurisdictions in Latin America,
the US and UK. The Company is led by Co-founder and Chief Executive
Officer, Alvaro Torres, together
with an experienced and diverse executive team and Board of
Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-and-tecnologico-de-monterrey-of-mexico-launch-first-internationally-accredited-medical-cannabis-diploma-in-latin-america-301232931.html
SOURCE Khiron Life Sciences Corp.